NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Zymeworks Inc (NYSE: ZYME)

 
ZYME Technical Analysis
5
As on 25th Jan 2022 ZYME Share Price closed @ 10.01 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 38.47 & Strong Sell for SHORT-TERM with Stoploss of 45.94 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ZYME Share Price

Open 9.89 Change Price %
High 10.32 1 Day 0.01 0.10
Low 9.54 1 Week -4.55 -31.25
Close 10.01 1 Month -6.06 -37.71
Volume 515463 1 Year -33.33 -76.90
52 Week High 56.81 | 52 Week Low 10.00
 
NYSE USA Most Active Stocks
DDR 15.44 -4.46%
F 19.98 -2.01%
BACA-U 302.00 0.67%
T 26.48 0.53%
BAC 45.43 1.98%
BBD 4.05 4.65%
RPAI 13.15 -3.17%
NIO 23.79 -4.34%
PBR 13.16 4.11%
PLTR 13.06 -2.54%
 
NYSE USA Top Gainers Stocks
BALY 35.85 22.65%
NINE 1.35 20.54%
NINE 1.35 20.54%
STEM-WT 14.40 17.74%
TRQ 17.50 15.89%
TRQ 17.50 15.89%
CZZ 0.17 13.33%
CZZ 0.17 13.33%
BQ 0.70 12.90%
CELP 1.06 12.77%
 
NYSE USA Top Losers Stocks
QFTA-WS 0.46 -95.33%
TWND-WS 0.48 -95.12%
CHAA-WS 0.53 -94.56%
PMVC-WS 0.58 -94.10%
PIAI-WS 0.58 -94.09%
PCPC-WS 1.50 -93.83%
FTEV-WS 0.60 -93.81%
PSTH-WS 1.25 -93.65%
PDOT-WS 0.62 -93.65%
CLAA-WS 0.75 -92.26%
 
 
ZYME
Daily Charts
ZYME
Intraday Charts
Whats New @
Bazaartrend
ZYME
Free Analysis
 
ZYME Important Levels Intraday
RESISTANCE11.51
RESISTANCE11.03
RESISTANCE10.73
RESISTANCE10.44
SUPPORT9.58
SUPPORT9.29
SUPPORT8.99
SUPPORT8.51
 
ZYME Target for Month January
4th UP TARGET42.83
3rd UP TARGET32.3
2nd UP TARGET25.8
1st UP TARGET19.29
1st DOWN TARGET0.73
2nd DOWN TARGET-5.78
3rd DOWN TARGET-12.28
4th DOWN TARGET-22.81
 
ZYME Weekly Target
4th UP TARGET18.01
3rd UP TARGET15.44
2nd UP TARGET13.86
1st UP TARGET12.27
1st DOWN TARGET7.75
2nd DOWN TARGET6.16
3rd DOWN TARGET4.58
4th DOWN TARGET2.01
 
ZYME Target for Year 2022
4th UP TARGET105.57
3rd UP TARGET74.92
2nd UP TARGET55.98
1st UP TARGET37.04
1st DOWN TARGET-17.02
2nd DOWN TARGET-35.96
3rd DOWN TARGET-54.9
4th DOWN TARGET-85.55
 
 
ZYME Other Details
Segment EQ
Market Capital 1054913664.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ZYME Address
ZYME
 
ZYME Latest News
 
Your Comments and Response on Zymeworks Inc
 
ZYME Business Profile
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Address: 1385 West 8th Avenue, Vancouver, BC, Canada, V6H 3V9
 
© 2005-2021 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service